Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
Authors
Keywords
-
Journal
Frontiers in Cell and Developmental Biology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-10-09
DOI
10.3389/fcell.2020.582370
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overcoming acquired resistance of epidermal growth factor receptor‐mutant non–small‐cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)
- (2020) Hongjing Zang et al. CANCER
- Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes
- (2020) Nicole Kiweler et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Epigenetic therapy inhibits metastases by disrupting premetastatic niches
- (2020) Zhihao Lu et al. NATURE
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
- (2019) Debarati Banik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
- (2019) Jhanelle E. Gray et al. CLINICAL CANCER RESEARCH
- N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PDL-1 expression
- (2019) Samir Mehndiratta et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/EGFR mutation double‐positive lung cancer
- (2019) Shinji Takeuchi et al. CANCER SCIENCE
- Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes
- (2019) Patrick L. Leslie et al. Nature Communications
- Inhibition of HDAC6 Attenuates Tumor Growth of Non-Small Cell Lung Cancer
- (2019) Brian Deskin et al. Translational Oncology
- Targeting histone deacetylase SIRT1 selectively eradicates EGFR TKI-resistant cancer stem cells via regulation of mitochondrial oxidative phosphorylation in lung adenocarcinoma
- (2019) Jiangtao Sun et al. NEOPLASIA
- Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?
- (2018) ANTICANCER RESEARCH
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
- (2018) Amila Suraweera et al. Frontiers in Oncology
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial
- (2017) Clara Y.H. Choi et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase I study of LBH589 in combination with erlotinib for advanced aerodigestive tract cancers.
- (2017) J. E. Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success
- (2016) John A. Halsall et al. BIOESSAYS
- HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
- (2016) Hong Zheng et al. CLINICAL CANCER RESEARCH
- Take two: Combining immunotherapy with epigenetic drugs to tackle cancer
- (2016) Karen Weintraub NATURE MEDICINE
- Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms
- (2016) L Wang et al. Cell Death & Disease
- HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?
- (2016) Amer A Beg et al. Epigenomics
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- HDACs and HDAC Inhibitors in Cancer Development and Therapy
- (2016) Yixuan Li et al. Cold Spring Harbor Perspectives in Medicine
- The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells
- (2015) TOMAS GROH et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Epigenetic Modulation with HDAC Inhibitor CG200745 Induces Anti-Proliferation in Non-Small Cell Lung Cancer Cells
- (2015) Sung-Min Chun et al. PLoS One
- Alterations of immune response of non-small cell lung cancer with Azacytidine
- (2015) John Wrangle et al. Oncotarget
- Expression of Class I Histone Deacetylases Indicates Poor Prognosis in Endometrioid Subtypes of Ovarian and Endometrial Carcinomas
- (2015) Wilko Weichert et al. NEOPLASIA
- The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
- (2014) C. Costa et al. CLINICAL CANCER RESEARCH
- Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
- (2014) Sridurga Mithraprabhu et al. Epigenetics
- Suberoylanilide hydroxamic acid radiosensitizes tumor hypoxic cells in vitro through the oxidation of nitroxyl to nitric oxide
- (2014) Yuval Samuni et al. FREE RADICAL BIOLOGY AND MEDICINE
- Targeting Histone Deacetylases for Cancer Therapy: From Molecular Mechanisms to Clinical Implications
- (2014) Zhiming Li et al. International Journal of Biological Sciences
- Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation
- (2014) Kazutoshi Isobe et al. Journal of Thoracic Oncology
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies
- (2013) Wei-Jan Huang et al. CANCER LETTERS
- Formulation and evaluation of drug-loaded targeted magnetic microspheres for cancer therapy
- (2013) Duc Do et al. International Journal of Nanomedicine
- Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer
- (2013) Darryl T. Martin et al. Nanomedicine-Nanotechnology Biology and Medicine
- Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer
- (2013) J S Riley et al. Cell Death & Disease
- Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
- (2012) Samir E. Witta et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone Deacetylase Inhibitors in Non–Small-Cell Lung Cancer
- (2012) Samir Witta Journal of Thoracic Oncology
- Playing the End Game: DNA Double-Strand Break Repair Pathway Choice
- (2012) J. Ross Chapman et al. MOLECULAR CELL
- A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
- (2012) King Pan Ng et al. NATURE MEDICINE
- Mitochondrial Apoptosis and FAK Signaling Disruption by a Novel Histone Deacetylase Inhibitor, HTPB, in Antitumor and Antimetastatic Mouse Models
- (2012) Jiunn-Min Shieh et al. PLoS One
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells
- (2011) Chien-Te Li et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung
- (2011) Yoshihiro Minamiya et al. LUNG CANCER
- Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo
- (2011) Valentina Zuco et al. PLoS One
- BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors
- (2011) A. C. Faber et al. Cancer Discovery
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
- (2011) R. A. Juergens et al. Cancer Discovery
- Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
- (2010) Cliona Grant et al. Expert Review of Anticancer Therapy
- Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study
- (2010) Anne M. Traynor et al. Journal of Thoracic Oncology
- Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining
- (2010) Kyle M Miller et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Anti-Tumor Effect in Human Lung Cancer by a Combination Treatment of Novel Histone Deacetylase Inhibitors: SL142 or SL325 and Retinoic Acids
- (2010) Shaoteng Han et al. PLoS One
- Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer Cells
- (2010) William Brazelle et al. PLoS One
- Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung
- (2010) Yoshihiro Minamiya et al. TUMOR BIOLOGY
- A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways
- (2009) Jung Jin Hwang et al. ANTI-CANCER DRUGS
- Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824
- (2009) D. D. Vo et al. CANCER RESEARCH
- Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
- (2009) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of nickel, chromate, and arsenite on histone 3 lysine methylation
- (2009) Xue Zhou et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
- (2008) D. S. Schrump et al. CLINICAL CANCER RESEARCH
- Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer
- (2008) A. Van Den Broeck et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase 8 in Neuroblastoma Tumorigenesis
- (2008) I. Oehme et al. CLINICAL CANCER RESEARCH
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis
- (2008) Wilko Weichert et al. LANCET ONCOLOGY
- Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
- (2008) A. Miyanaga et al. MOLECULAR CANCER THERAPEUTICS
- DNA Methylation Markers and Early Recurrence in Stage I Lung Cancer
- (2008) Malcolm V. Brock et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started